Berotralstat for long-term prophylaxis of hereditary angioedema in Japan: Parts 2 and 3 of the randomized APeX-J Phase III trial

Background: Berotralstat is a once-daily oral inhibitor of plasma kallikrein for the prophylaxis of hereditary angioedema (HAE) in patients ≥12 years. APeX-J aimed to evaluate the efficacy and safety of berotralstat in Japan. Methods: APeX-J was a Phase III trial comprising 3 parts (NCT03873116). Pa...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Daisuke Honda, MD, PhD, Michihiro Hide, MD, PhD, Tomoo Fukuda, MD, PhD, Keisuke Koga, MD, PhD, Eishin Morita, MD, PhD, Shinichi Moriwaki, MD, Yoshihiro Sasaki, MD, PhD, Yusuke Suzuki, MD, PhD, Phil Collis, PhD, Douglas T. Johnston, DO, Dianne Tomita, MPH, Bhavisha Desai, PharmD, Isao Ohsawa, MD, PhD
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	Elsevier 2024-03-01
Serie:	World Allergy Organization Journal
Ämnen:	Angioedemas Hereditary Berotralstat Japan Plasma kallikrein Quality of life
Länkar:	http://www.sciencedirect.com/science/article/pii/S1939455124000139
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!